Vaxxinity (VAXX) Competitors $0.0050 +0.00 (+2,400.00%) As of 02/21/2025 09:54 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends VAXX vs. SCPS, EVLO, CMRA, GNCA, ARDS, CALA, AMPE, CLVR, EFTR, and ATNFWShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), and 180 Life Sciences (ATNFW). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Aridis Pharmaceuticals Calithera Biosciences Ampio Pharmaceuticals Clever Leaves eFFECTOR Therapeutics 180 Life Sciences Vaxxinity (NASDAQ:VAXX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Is VAXX or SCPS more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Scopus BioPharma N/A N/A N/A Does the MarketBeat Community prefer VAXX or SCPS? Vaxxinity received 3 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformVaxxinityOutperform Votes538.46% Underperform Votes861.54% Scopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes Do insiders & institutionals hold more shares of VAXX or SCPS? 82.9% of Vaxxinity shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has stronger valuation and earnings, VAXX or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.45-0.01Scopus BioPharmaN/AN/A-$11.61MN/AN/A Does the media refer more to VAXX or SCPS? In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Vaxxinity Neutral Scopus BioPharma Neutral Which has more volatility & risk, VAXX or SCPS? Vaxxinity has a beta of -18.15, suggesting that its stock price is 1,915% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. SummaryVaxxinity and Scopus BioPharma tied by winning 3 of the 6 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25,000.00$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.016.1326.4618.82Price / SalesN/A311.22453.6978.73Price / CashN/A67.8344.0437.47Price / Book0.056.747.634.64Net Income-$56.93M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.43%-1.91%-2.66%1 Month PerformanceN/A-1.91%-0.19%-2.15%1 Year PerformanceN/A-5.03%16.70%12.90% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.01+2,400.0%N/A-99.3%$30,000.00N/A-0.0190High Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/A-91.7%$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A-95.3%$9,000.00N/A0.00120Options VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/A-99.4%$6,000.00$630,000.000.002High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5,000.00$3.09M0.0030High Trading VolumeCALACalithera BiosciencesN/A$0.00flatN/A-97.0%$3,000.00N/A0.0060Analyst ForecastNews CoverageAMPEAmpio PharmaceuticalsN/A$0.00-79.0%N/A-99.9%$2,000.00N/A0.0020Analyst ForecastNews CoverageHigh Trading VolumeCLVRClever LeavesN/A$0.00-50.0%N/A-100.0%$2,000.00$17.42M0.00560Gap UpHigh Trading VolumeEFTReFFECTOR Therapeutics1.0633 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010ATNFW180 Life SciencesN/A$0.01+6.5%N/A+51.5%$0.00N/A0.007News CoveragePositive NewsGap Down Related Companies and Tools Related Companies Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Calithera Biosciences Competitors Ampio Pharmaceuticals Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors 180 Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VAXX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
